EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple‐Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden

Atif Ali Hashmi iD, Noreen Wahid, Ghazala Mudassir, Muhammad Irfan iD, Umair Arshad Malik iD, Erum Yousuf Khan, Syed Muhammad Abu Bakar, Naveen Faridi

The Breast Journal · 2025-01 · 2025 (1)

DOI: 10.1155/tbj/8856567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Breast Journal, online erschienen am 30.09.2025. Verfasst von Atif Ali Hashmi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histopathology, Liaquat National Hospital and Medical College, Karachi, Pakistan. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Programmed death ligand 1 (PDL1) expression in tumors is linked to immune evasion in various cancers, making these patients potential candidates for PDL1 inhibitors. Although immune checkpoint blockade therapy has gained approval for breast cancer treatment, especially triple‐negative breast cancer (TNBC), there is a lack of PDL1 expression data in Pakistani breast cancer patients. In our study, PDL1 expression was assessed in TNBC to determine eligibility for PDL1 inhibitors. Our study aimed to evaluate the frequency of PDL1 expression in TNBC. We also examined how PDL1 expression correlates with clinicopathological characteristics and prognostic factors in patients with TNBC. Moreover, the association of neoadjuvant chemotherapy response with PDL1 expression was also evaluated.

Methods

This cross‐sectional study was conducted at the Liaquat National Hospital Histopathology Department from January 2022 to June 2023. A total of 128 biopsy‐proven cases of TNBCs were administered neoadjuvant chemotherapy before surgery during this period. PDL1 immunohistochemical staining was performed on prechemotherapy needle biopsies. Expression was determined using the combined positive score (CPS). CPS is the number of PDL1‐stained cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells multiplied by 100. Cases with CPS ≥ 10 were considered PDL1‐positive.

Results

Complete pathological response (pCR) was observed in 32.8% ( n = 42) of cases. PDL1 expression was observed in 18.8% ( n = 24) of cases. The majority of cases showed a high residual cancer burden (RCB‐III) ( n = 53, 41.4%). A significant association was noted between PDL1 expression and neoadjuvant chemotherapy response ( p < 0.01). PDL1‐positive cases had a higher pCR ( n = 16, 66.7%) than PDL1‐negative cases ( n = 26, 25%). PDL1‐positive cases showed a lower frequency of RCB‐II‐III (RCB‐II: 8.3%; RCB‐III: 0%) than PDL1‐negative cases (RCB‐II: 25%; RCB‐III: 51%), with a significant p value ( p < 0.01).

Conclusion

Overall, PDL1 expression was low in TNBC cases in our study; however, identifying these cases is important to identify those that can benefit from immunotherapy. We found a significant association of PDL1 expression with neoadjuvant chemotherapy response and RCB. Moreover, PDL1 positivity was associated with lower Ki67 index and older age. Therefore, we recommend routine PDL1 testing in all cases of TNBC to predict neoadjuvant chemotherapy response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsB7-H1 AntigenHumansFemaleMiddle AgedNeoadjuvant TherapyCross-Sectional StudiesAdultAgedNeoplasm, ResidualPrognosisBiomarkers, Tumor

Stichwörter der Autor:innen

chemotherapy responsepredictive markersprognostic markersprogrammed death ligand 1 (PDL1)triple-negative breast cancer

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Histopathology, Liaquat National Hospital and Medical College, Karachi, Pakistan.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pathology, Shifa College of Dentistry, Shifa Tameer-e-Millat University, Rawalpindi, Pakistan.
  • Department of Statistics, Liaquat National Hospital and Medical College, Karachi, Pakistan.
  • College of Osteopathic Medicine, Garden City Hospital, Michigan State University, Garden City, Michigan, USA.

ORCID-Profile: Atif Ali Hashmi, Muhammad Irfan, Umair Arshad Malik

Förderung

  • NCI NIH HHS

Zitieren

APA

Hashmi, A. A., Wahid, N., Mudassir, G., Irfan, M., Malik, U. A., Khan, E. Y., Abu Bakar, S. M., & Faridi, N. (2025). Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple‐Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden. The Breast Journal, 2025(1). https://doi.org/10.1155/tbj/8856567

Vancouver

Hashmi AA, Wahid N, Mudassir G, Irfan M, Malik UA, Khan EY, et al. Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple‐Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden. The Breast Journal. 2025;2025(1). doi:10.1155/tbj/8856567

BibTeX
@article{Hashmi2025,
  author = {Hashmi, Atif Ali and Wahid, Noreen and Mudassir, Ghazala and Irfan, Muhammad and Malik, Umair Arshad and Khan, Erum Yousuf and Abu Bakar, Syed Muhammad and Faridi, Naveen},
  title = {Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple‐Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden},
  journal = {The Breast Journal},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/tbj/8856567}
}
Kostenlos starten →